ArticleiGIE : innovation, investigation and insights2024
Novel hemostatic adhesive powder to prevent delayed bleeding after endoscopic submucosal dissection in the GI tract: first U.S. multicenter experience.
Article in iGIE : innovation, investigation and insights, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Effect of Prophylactic Colon ESD (Endoscopic Submucosal Dissection) Defect Closure on Post-ESD Outcomes: An International Multi-center Retrospective Study.Digestive diseases and sciences · 2026Article
- Traction-Assisted Endoscopic Submucosal Dissection with Novel Hemostatic Powder Application for a Carbon Nanoparticle-Tattooed Colonic Lesion.Endoscopy international open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Delayed bleeding (DB) is a common adverse event after endoscopic submucosal dissection (ESD). We evaluated a novel hemostatic powder (UI-EWD, Nexpowder; Medtronic, Minneapolis, Minn, USA) to prevent DB after ESD. Methods: This was a multicenter retrospective analysis of ESDs performed between January 2023 and March 2024 in which UI-EWD was applied to prevent DB. Cases in which endoscopic closure of the post-ESD mucosal defect was performed were excluded. DB was defined as a bleeding event requiring hospitalization, blood transfusion, or any intervention within 30 days after the procedure. Technical success of UI-EWD was defined as successful delivery and application of the hemostatic powder over the entire mucosal defect. Results: Eighty-three patients (median age, 66 years) underwent ESD in the esophagus (n = 18), stomach (n = 15), colon (n = 38), and rectum (n = 12). The median lesion size was 50 mm (interquartile range, 41-70 mm). UI-EWD was successfully applied in all defects, although in 2 cases (2.4%) a second delivery catheter had to be used to complete the procedure. DB occurred in 3 patients (3.6%): 2 after gastric ESD and 1 after colonic ESD within 24 hours of the index procedure. None required intervention on repeat endoscopy. There were no cases of perforation. En bloc and R0 resection rates were 96.2% and 88.7%, respectively. Conclusions: UI-EWD can be easily applied to mucosal defects after ESD throughout the GI tract. Initial data from this multicenter study demonstrate that the use of UI-EWD was associated with a relatively low rate of DB after ESD. Additional comparative studies are needed to corroborate these preliminary findings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.